119 related articles for article (PubMed ID: 1969949)
1. Influence of lignocaine on plasma protein binding and pharmacokinetics of verapamil in dogs.
Belpaire FM; De Rick A; Bourda A; De Smet F; Rosseel MT; Bogaert MG
J Pharm Pharmacol; 1990 Jan; 42(1):45-9. PubMed ID: 1969949
[TBL] [Abstract][Full Text] [Related]
2. Influence of lidocaine on plasma protein binding and pharmacokinetics of verapamil in dogs.
Belpaire FM; De Rick A; De Smet F; Bourda A; Rosseel MT; Bogaert MG
Prog Clin Biol Res; 1989; 300():437-40. PubMed ID: 2780641
[No Abstract] [Full Text] [Related]
3. Protein binding and disposition of lignocaine in the elderly.
Cusack B; O'Malley K; Lavan J; Noel J; Kelly JG
Eur J Clin Pharmacol; 1985; 29(3):323-9. PubMed ID: 4076329
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil.
Chelly JE; Hill DC; Abernethy DR; Dlewati A; Doursout MF; Merin RG
J Pharmacol Exp Ther; 1987 Oct; 243(1):211-6. PubMed ID: 3668853
[TBL] [Abstract][Full Text] [Related]
5. Influence of enhanced alpha-1-acid glycoprotein concentration on protein binding, pharmacokinetics and antiarrhythmic effect of lidocaine in the dog.
De Rick AF; Belpaire FM; Dello C; Bogaert MG
J Pharmacol Exp Ther; 1987 Apr; 241(1):289-93. PubMed ID: 3572791
[TBL] [Abstract][Full Text] [Related]
6. On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.
Barchowsky A; Shand DG; Stargel WW; Wagner GS; Routledge PA
Br J Clin Pharmacol; 1982 Mar; 13(3):411-5. PubMed ID: 7059443
[TBL] [Abstract][Full Text] [Related]
7. Lignocaine and indocyanine green kinetics in patients following myocardial infarction.
Bax ND; Tucker GT; Woods HF
Br J Clin Pharmacol; 1980 Oct; 10(4):353-61. PubMed ID: 7448106
[TBL] [Abstract][Full Text] [Related]
8. Decreased binding of verapamil to plasma proteins in patients with liver disease.
Giacomini KM; Massoud N; Wong FM; Giacomini JC
J Cardiovasc Pharmacol; 1984; 6(5):924-8. PubMed ID: 6209501
[TBL] [Abstract][Full Text] [Related]
9. Effect of lignocaine on arginine-vasopressin plasma levels: baseline or induced by frusemide.
Gariépy L; Larose P; Bailey B; du Souich P
Br J Pharmacol; 1992 Jun; 106(2):470-5. PubMed ID: 1393272
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting the plasma protein binding of verapamil and norverapamil in man.
Yong CL; Kunka RL; Bates TR
Res Commun Chem Pathol Pharmacol; 1980 Nov; 30(2):329-39. PubMed ID: 7444161
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of lignocaine.
Benowitz NL; Meister W
Clin Pharmacokinet; 1978; 3(3):177-201. PubMed ID: 350470
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the enantiomers of verapamil in the dog.
Bai SA; Lankford SM; Johnson LM
Chirality; 1993; 5(6):436-42. PubMed ID: 8398603
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.
Nattel S; Gagne G; Pineau M
Clin Pharmacokinet; 1987 Nov; 13(5):293-316. PubMed ID: 2891461
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit.
De Cicco M; Macor F; Robieux I; Zanette G; Fantin D; Fabiani F; Nicolosi G; Fracasso A; Toffoli G; Santantonio C; Lestuzzi C; Matovic M; Boiocchi M
Crit Care Med; 1999 Feb; 27(2):332-9. PubMed ID: 10075058
[TBL] [Abstract][Full Text] [Related]
15. Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans.
Manitpisitkul P; Chiou WL
Biopharm Drug Dispos; 1993 Oct; 14(7):555-66. PubMed ID: 8251610
[TBL] [Abstract][Full Text] [Related]
16. Verapamil pharmacokinetics and liver function in patients with cirrhosis.
Finucci GF; Padrini R; Piovan D; Melica E; Merkel C; Gatta A; Zuin R
Int J Clin Pharmacol Res; 1988; 8(2):123-6. PubMed ID: 3378854
[TBL] [Abstract][Full Text] [Related]
17. Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.
Tucker GT; Bax ND; Lennard MS; Al-Asady S; Bharaj HS; Woods HF
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):21S-28S. PubMed ID: 6146336
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of local lignocaine-induced sensory block by calcium channel blockers in rats.
Iwasaki H; Ohmori H; Omote K; Kawamata M; Sumita S; Yamauchi M; Namiki A
Br J Anaesth; 1996 Aug; 77(2):243-7. PubMed ID: 8881634
[TBL] [Abstract][Full Text] [Related]
19. Lignocaine disposition in blood in epilepsy.
Routledge PA; Stargel WW; Finn AL; Barchowsky A; Shand DG
Br J Clin Pharmacol; 1981 Nov; 12(5):663-6. PubMed ID: 7332731
[TBL] [Abstract][Full Text] [Related]
20. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
